Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salbutamol vs Placebo on Dyspnea and Exercise Tolerance in Adults With Cystic Fibrosis
NCT03522831Active, not recruiting
- Sponsor
- University of British Columbia
- Start
- May 2018
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of salbutamol in cystic fibrosis (CF) (2 arms), sponsored by University of British Columbia. Primary endpoint: Standardized dyspnea score at the highest equivalent submaximal exercise time. Started May 2018; status: active, not recruiting.
02
Drugs
salbutamol
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03522831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03522831.